Complete Filing Data
Lexeo Therapeutics, Inc. reported Stockholders Equity of $246.67 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Lexeo Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income * | -$100.0M | -$98.3M | -$66.4M | -$59.3M |
| Research And Development Expense | $63.8M | $74.1M | $53.1M | $49.2M |
| Operating Income Loss | -$109.3M | -$105.8M | -$68.5M | -$60.5M |
| Operating Expenses | $109.3M | $105.8M | $68.5M | $61.2M |
| Nonoperating Income Expense | $9.3M | $7.4M | $2.1M | $1.2M |
| General And Administrative Expense | $45.5M | $31.7M | $15.4M | $12.0M |
| Other Nonoperating Income Expense | -$18.0K | -$9.0K | -$13.0K | -$2.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$98.3M | -$66.4M | -$59.3M | |
| Interest Expense Nonoperating | $95.0K | $137.0K | $205.0K | |
| Interest Expense | $205.0K | $91.0K | ||
| Comprehensive Income Net Of Tax | -$99.7M | -$98.4M | -$66.4M | |
| Other Comprehensive Income Loss Net Of Tax | $291.0K | -$103.0K | ||
| Revenue From Contract With Customer Excluding Assessed Tax | $654.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$20.3M | -$26.1M | -$32.7M | -$29.5M | -$21.2M | -$21.7M | -$20.1M | -$13.4M | -$18.7M | -$17.1M | -$15.1M | -$12.5M |
| Research And Development Expense | $15.7M | $14.7M | $17.2M | $23.4M | $16.6M | $15.7M | $17.2M | $11.2M | $16.4M | $15.4M | ||
| Operating Income Loss | -$21.6M | -$30.7M | -$33.8M | -$31.5M | -$23.6M | -$23.3M | -$20.3M | -$14.0M | -$19.3M | -$17.5M | ||
| Operating Expenses | $21.6M | $30.7M | $33.8M | $31.5M | $23.6M | $23.3M | $20.3M | $14.0M | $19.3M | $18.0M | ||
| Nonoperating Income Expense | $1.4M | $4.6M | $1.1M | $2.1M | $2.3M | $1.6M | $165.0K | $534.0K | $633.0K | $427.0K | ||
| General And Administrative Expense | $6.0M | $16.0M | $16.6M | $8.1M | $7.0M | $7.5M | $3.0M | $2.7M | $2.9M | $2.7M | ||
| Other Nonoperating Income Expense | -$9.0K | -$14.0K | -$4.0K | -$3.0K | -$1.0K | -$5.0K | $1.0K | -$3.0K | -$4.0K | |||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$20.3M | -$26.1M | -$32.7M | -$29.5M | -$21.2M | -$21.7M | -$20.1M | -$13.4M | -$18.7M | -$17.1M | ||
| Interest Expense Nonoperating | $22.0K | $25.0K | $28.0K | $35.0K | $35.0K | $37.0K | $52.0K | |||||
| Interest Expense | $35.0K | $37.0K | $52.0K | $53.0K | $50.0K | $29.0K | ||||||
| Comprehensive Income Net Of Tax | -$20.2M | -$26.1M | -$32.6M | -$29.5M | -$21.2M | -$21.7M | ||||||
| Other Comprehensive Income Loss Net Of Tax | $102.0K | $41.0K | $49.0K | |||||||||
| Revenue From Contract With Customer Excluding Assessed Tax | $531.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Stockholders Equity | $246.7M | $116.8M | $113.5M | -$113.0M | -$55.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $66.2M | $38.3M | $124.7M | $80.6M | $135.9M |
| Finance Lease Right Of Use Asset Amortization | $320.0K | $325.0K | $306.0K | $148.0K | |
| Finance Lease Principal Payments | $533.0K | $410.0K | $425.0K | $163.0K | |
| Cash And Cash Equivalents At Carrying Value | $63.0M | $35.0M | $121.5M | $77.3M | $135.9M |
| Retained Earnings Accumulated Deficit | -$380.1M | -$280.2M | -$181.8M | -$115.4M | |
| Restricted Cash Noncurrent | $3.2M | $3.3M | $3.3M | $3.3M | |
| Property Plant And Equipment Net | $1.1M | $1.0M | $1.1M | $998.0K | |
| Operating Lease Right Of Use Asset Amortization Expense | $1.5M | $1.4M | $1.3M | $877.0K | |
| Operating Lease Right Of Use Asset | $6.6M | $8.1M | $9.4M | $10.7M | |
| Operating Lease Liability Noncurrent | $4.9M | $6.4M | $7.8M | $9.0M | |
| Operating Lease Liability Current | $2.2M | $2.1M | $2.1M | $2.3M | |
| Liabilities Current | $16.8M | $22.8M | $17.2M | $14.3M | |
| Liabilities And Stockholders Equity | $268.7M | $146.9M | $139.8M | $97.1M | |
| Liabilities | $22.0M | $30.1M | $26.3M | $25.0M | |
| Finance Lease Right Of Use Asset | $1.1M | $1.5M | $1.8M | $2.1M | |
| Finance Lease Liability Noncurrent | $327.0K | $817.0K | $1.2M | $1.6M | |
| Finance Lease Liability Current | $518.0K | $570.0K | $518.0K | $547.0K | |
| Common Stock Value | $7.0K | $3.0K | $3.0K | $0.00 | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $28.0M | -$86.5M | $44.1M | -$55.3M | |
| Assets Current | $188.4M | $126.1M | $124.3M | $80.0M | |
| Assets | $268.7M | $146.9M | $139.8M | $97.1M | |
| Amounts Reclassified From Deposit Liabilities Upon The Vesting Of Early Exercised Stock Options Previously Subject To Repurchase Net Of Proceeds Received From Early Exercise Of Unvested Stock Options Subject To Repurchase And Record | $37.0K | $59.0K | $87.0K | -$188.0K | |
| Additional Paid In Capital Common Stock | $626.6M | $397.1M | $295.4M | $2.5M | |
| Accrued Liabilities And Other Liabilities Current | $9.3M | $13.8M | $10.8M | $6.4M | |
| Accounts Payable Current | $4.9M | $6.4M | $3.8M | $2.7M | |
| Prepaid Expense And Other Assets Current | $6.6M | $4.6M | $2.8M | ||
| Treasury Stock Common Shares | 3.8K | 3.8K | 0.00 | ||
| Unrealized Gain Loss On Investments | $291.0K | -$103.0K | |||
| Treasury Stock Common Value | $17.0K | $17.0K | |||
| Finance Lease Right Of Use Assets And Finance Lease Liabilities Recognized | $22.0K | $2.4M | |||
| Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction | $50.0K | ||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $188.0K | -$103.0K | |||
| Accrued Bonuses Current | $1.9M | ||||
| Treasury Stock Repurchase | $17.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $120.8M | $138.2M | $88.1M | $139.3M | $164.9M | $183.0M | -$162.8M | -$143.6M | -$131.2M | -$99.0M | -$82.4M | -$67.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $44.2M | $38.7M | $32.2M | $160.3M | $178.2M | $198.3M | $38.7M | $48.8M | $62.1M | $97.4M | |||
| Finance Lease Right Of Use Asset Amortization | $80.0K | $80.0K | $80.0K | $80.0K | $80.0K | $85.0K | $79.0K | $79.0K | $69.0K | $46.0K | |||
| Finance Lease Principal Payments | $83.0K | $122.0K | $159.0K | $111.0K | $74.0K | $109.0K | $107.0K | $103.0K | $110.0K | $36.0K | |||
| Cash And Cash Equivalents At Carrying Value | $41.0M | $35.5M | $28.9M | $157.0M | $175.0M | $195.1M | $35.4M | $94.2M | |||||
| Retained Earnings Accumulated Deficit | -$359.2M | -$338.9M | -$312.8M | -$254.2M | -$224.8M | -$224.8M | -$167.7M | ||||||
| Restricted Cash Noncurrent | $3.2M | $3.2M | $3.2M | $3.3M | $3.3M | $3.3M | $3.3M | $3.2M | |||||
| Property Plant And Equipment Net | $1.2M | $1.1M | $1.0M | $1.2M | $1.2M | $1.0M | $980.0K | ||||||
| Operating Lease Right Of Use Asset Amortization Expense | $361.0K | $322.0K | $321.0K | ||||||||||
| Operating Lease Right Of Use Asset | $7.0M | $7.3M | $7.7M | $8.4M | $8.8M | $9.1M | $9.8M | ||||||
| Operating Lease Liability Noncurrent | $5.3M | $5.7M | $6.1M | $6.8M | $7.1M | $7.5M | $8.1M | ||||||
| Operating Lease Liability Current | $2.1M | $2.1M | $2.1M | $2.1M | $2.1M | $2.1M | $2.1M | ||||||
| Liabilities Current | $17.3M | $31.6M | $30.8M | $26.8M | $18.9M | $21.6M | $23.0M | ||||||
| Liabilities And Stockholders Equity | $143.8M | $176.1M | $125.7M | $173.9M | $192.0M | $213.2M | $54.7M | ||||||
| Liabilities | $23.0M | $37.9M | $37.6M | $34.5M | $27.1M | $30.3M | $32.5M | ||||||
| Finance Lease Right Of Use Asset | $1.2M | $1.3M | $1.4M | $1.5M | $1.6M | $1.7M | $1.8M | ||||||
| Finance Lease Liability Noncurrent | $454.0K | $577.0K | $698.0K | $930.0K | $1.0M | $1.2M | $1.4M | ||||||
| Finance Lease Liability Current | $568.0K | $520.0K | $521.0K | $574.0K | $572.0K | $524.0K | $519.0K | ||||||
| Common Stock Value | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $0.00 | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$6.1M | $73.6M | -$18.5M | ||||||||||
| Assets Current | $127.8M | $140.1M | $105.3M | $159.5M | $177.1M | $198.1M | $38.9M | ||||||
| Assets | $143.8M | $176.1M | $125.7M | $173.9M | $192.0M | $213.2M | $54.7M | ||||||
| Amounts Reclassified From Deposit Liabilities Upon The Vesting Of Early Exercised Stock Options Previously Subject To Repurchase Net Of Proceeds Received From Early Exercise Of Unvested Stock Options Subject To Repurchase And Record | $13.0K | $3.0K | $21.0K | ||||||||||
| Additional Paid In Capital Common Stock | $480.0M | $477.2M | $401.0M | $393.6M | $389.7M | $386.5M | $4.8M | ||||||
| Accrued Liabilities And Other Liabilities Current | $9.9M | $8.9M | $16.2M | $15.7M | $10.4M | $13.8M | $11.8M | ||||||
| Accounts Payable Current | $4.7M | $20.0M | $12.0M | $8.4M | $5.8M | $4.3M | $2.7M | ||||||
| Prepaid Expense And Other Assets Current | $5.0M | $7.2M | $5.4M | $2.4M | $2.2M | $3.0M | |||||||
| Treasury Stock Common Shares | 3.8K | 3.8K | 3.8K | 3.0K | 3.0K | ||||||||
| Unrealized Gain Loss On Investments | $102.0K | $41.0K | $49.0K | ||||||||||
| Treasury Stock Common Value | $17.0K | $17.0K | $17.0K | $13.0K | $13.0K | ||||||||
| Finance Lease Right Of Use Assets And Finance Lease Liabilities Recognized | $22.0K | ||||||||||||
| Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction | $51.0K | ||||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $89.0K | -$13.0K | -$54.0K | ||||||||||
| Accrued Bonuses Current | $950.0K | $2.8M | $1.8M | ||||||||||
| Treasury Stock Repurchase |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stock Issued During Period Value Share Based Compensation | $12.1M | $12.5M | $3.0M | $1.8M |
| Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options | $37.0K | $59.0K | $87.0K | -$188.0K |
| Share Based Compensation | $12.1M | $12.5M | $3.0M | $1.8M |
| Net Cash Provided By Used In Operating Activities | -$98.6M | -$81.2M | -$59.5M | -$54.6M |
| Net Cash Provided By Used In Financing Activities | $216.8M | $88.8M | $103.8M | $189.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $2.0M | $1.7M | -$990.0K | $1.9M |
| Increase Decrease In Operating Lease Liability | -$1.5M | -$1.3M | -$1.4M | -$298.0K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$4.4M | $3.4M | $2.1M | $4.5M |
| Increase Decrease In Accounts Payable | -$1.6M | $2.4M | -$180.0K | -$426.0K |
| Net Cash Provided By Used In Investing Activities | -$90.3M | -$94.1M | -$165.0K | -$901.0K |
| Proceeds From Stock Options Exercised | $59.0K | $491.0K | $51.0K | $332.0K |
| Payments To Acquire Property Plant And Equipment | $397.0K | $481.0K | $115.0K | $672.0K |
| Increase Decrease In Finance Lease Liability | -$9.0K | $10.0K | -$5.0K | -$6.0K |
| Payments To Acquire Software | $0.00 | $50.0K | $229.0K | |
| Proceeds From Issuance Of Private Placement | $95.0M | |||
| Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options Unvested Stock Options Subject To Repurchase Value | $87.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Share Based Compensation | $2.7M | $3.1M | $3.7M | $3.8M | $2.8M | $2.3M | $873.0K | $969.0K | $397.0K | $431.0K | $554.0K | $275.0K |
| Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options | $8.0K | $12.0K | $13.0K | $14.0K | $26.0K | $3.0K | $16.0K | $26.0K | $21.0K | $64.0K | -$69.0K | -$235.0K |
| Share Based Compensation | $3.7M | $2.3M | $875.0K | $397.0K | $431.0K | |||||||
| Net Cash Provided By Used In Operating Activities | -$21.7M | -$14.9M | -$18.4M | |||||||||
| Net Cash Provided By Used In Financing Activities | $11.0K | $88.7M | -$98.0K | |||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $362.0K | $201.0K | -$524.0K | |||||||||
| Increase Decrease In Operating Lease Liability | -$357.0K | -$315.0K | -$332.0K | |||||||||
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $2.3M | $3.9M | -$1.8M | |||||||||
| Increase Decrease In Accounts Payable | $5.1M | $639.0K | $1.0M | |||||||||
| Net Cash Provided By Used In Investing Activities | $15.6M | -$193.0K | ||||||||||
| Proceeds From Stock Options Exercised | $10.0K | $12.0K | ||||||||||
| Payments To Acquire Property Plant And Equipment | $185.0K | |||||||||||
| Increase Decrease In Finance Lease Liability | -$9.0K | -$8.0K | ||||||||||
| Payments To Acquire Software | $8.0K | |||||||||||
| Proceeds From Issuance Of Private Placement | $88.8M | |||||||||||
| Adjustments To Additional Paid In Capital Reclassification From Deposit Liability Share Based Compensation And Exercise Of Stock Options Unvested Stock Options Subject To Repurchase Value | $3.0K | $21.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 53.6M | 31.8M | 5.4M | 1.6M |
| Weighted Average Number Of Diluted Shares Outstanding | 53.6M | 31.8M | 5.4M | 1.6M |
| Earnings Per Share Diluted | $-1.86 | $-3.09 | $-12.40 | $-36.36 |
| Earnings Per Share Basic | $-1.86 | $-3.09 | $-12.40 | $-36.36 |
| Common Stock Shares Outstanding | 73.0M | 33.1M | 26.6M | 1.6M |
| Common Stock Shares Issued | 73.0M | 33.1M | 26.7M | 1.6M |
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 18.1M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Temporary Equity Shares Outstanding | 143.7M | 143.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 61.0M | 43.6M | 33.1M | 33.1M | 33.0M | 28.0M | 1.6M | 1.6M | 1.6M | 1.6M |
| Weighted Average Number Of Diluted Shares Outstanding | 61.0M | 43.6M | 33.1M | 33.1M | 33.0M | 28.0M | 1.6M | 1.6M | 1.6M | 1.6M |
| Earnings Per Share Diluted | $-0.33 | $-0.60 | $-0.99 | $-0.89 | $-0.64 | $-0.77 | $-12.36 | $-8.30 | $-11.58 | $-10.38 |
| Earnings Per Share Basic | $-0.33 | $-0.60 | $-0.99 | $-0.89 | $-0.64 | $-0.77 | $-12.36 | $-8.30 | $-11.58 | $-10.38 |
| Common Stock Shares Outstanding | 54.9M | 54.0M | 33.2M | 33.1M | 33.0M | 32.9M | 1.6M | |||
| Common Stock Shares Issued | 54.9M | 54.0M | 33.2M | 33.1M | 33.1M | 32.9M | 1.7M | |||
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 18.1M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Temporary Equity Shares Outstanding | 143.7M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $59.0K | $491.0K | $51.0K | $332.0K |
| Investment Income Interest | $6.1M | $7.6M | $2.9M | $1.3M |
| Depreciation And Amortization | $268.0K | $304.0K | $271.0K | $120.0K |
| Capital Expenditures Incurred But Not Yet Paid Net Of Paid Amount | -$120.0K | -$141.0K | ||
| Stock Issued During Period Value New Issues Additional Offering Costs Incurred | -$24.0K | |||
| Interest Paid Net | $104.0K | $127.0K | $176.0K | $77.0K |
| Gain Loss On Fair Value Hedges Recognized In Earnings | -$530.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $34.0K | $39.0K | $419.0K | $10.0K | $30.0K | $9.0K | $12.0K | $69.0K | $235.0K | |||
| Investment Income Interest | $1.5M | $1.3M | $1.2M | $2.1M | $2.3M | $1.7M | $488.0K | $590.0K | $687.0K | $456.0K | ||
| Depreciation And Amortization | $60.0K | $69.0K | $57.0K | |||||||||
| Capital Expenditures Incurred But Not Yet Paid Net Of Paid Amount | -$77.0K | $136.0K | ||||||||||
| Stock Issued During Period Value New Issues Additional Offering Costs Incurred | $24.0K | -$42.0K | ||||||||||
| Interest Paid Net | ||||||||||||
| Gain Loss On Fair Value Hedges Recognized In Earnings | -$272.0K |
Most recent annual filing with the SEC: March 30, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.